Samsung Pharm Cash Flow-to-Debt Ratio
Samsung Pharm cash flow-to-debt ratio. Samsung Pharm (001360) has a Cash Flow-to-Debt Ratio of -0.05x as of September 2025, meaning its operating cash flow of ₩-2.29 Billion could theoretically repay 0% of its total liabilities (₩44.04 Billion) in one year. Check Samsung Pharm (001360) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Samsung Pharm (2012–2024)
Cash flow-to-debt ratio of Samsung Pharm from 2012 to 2024. Historical debt coverage capacity for Samsung Pharm across 12 annual periods. Check total reinvestment intensity of Samsung Pharm to assess the company's total reinvestment commitment from operating cash flow.
Samsung Pharm Cash Flow-to-Debt Ratio by Year (2012–2024)
Samsung Pharm cash flow-to-debt ratio by year from 2012 to 2024. Year-by-year debt coverage analysis for Samsung Pharm. For the full cash flow conversion analysis, see Samsung Pharm (001360) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.77x | ₩-17.30 Billion | ₩22.60 Billion | ▲ +56.0% |
| 2023 | -1.74x | ₩-27.66 Billion | ₩15.89 Billion | ▼ -1293.0% |
| 2022 | -0.12x | ₩-1.91 Billion | ₩15.32 Billion | ▲ +68.3% |
| 2021 | -0.39x | ₩-7.16 Billion | ₩18.19 Billion | ▼ -776.4% |
| 2020 | -0.04x | ₩-2.55 Billion | ₩56.81 Billion | ▲ +52.5% |
| 2019 | -0.09x | ₩-2.43 Billion | ₩25.70 Billion | ▲ +57.9% |
| 2018 | -0.22x | ₩-6.52 Billion | ₩28.98 Billion | ▼ -363.4% |
| 2017 | 0.09x | ₩5.15 Billion | ₩60.33 Billion | ▲ +148.0% |
| 2016 | -0.18x | ₩-9.94 Billion | ₩55.91 Billion | ▼ -255.1% |
| 2015 | -0.05x | ₩-4.20 Billion | ₩83.98 Billion | ▲ +87.4% |
| 2014 | -0.40x | ₩-13.58 Billion | ₩34.12 Billion | ▼ -144.4% |
| 2012 | -0.16x | ₩-11.13 Billion | ₩68.31 Billion | — |